Few developments in modern medicine have generated as much clinical attention — or public interest — as the emergence of injectable treatments for obesity and type 2 diabetes. Liraglutide, semaglutide, and tirzepatide belong to a class of medications that work through the body’s own hormonal pathways to regulate appetite, blood glucose, and weight. While they share a common lineage, they differ meaningfully in how they work, how effective they are, how they are administered, and what side effects a patient might experience. Understanding these distinctions is an important foundation for any informed conversation about treatment.
What Are These Medications?
All three belong to a broader class of treatments known as incretin-based therapies, which work by mimicking or enhancing the effects of hormones naturally released by the gut after eating. Liraglutide, marketed as Victoza for diabetes and Saxenda for weight management, was the first of the three to be approved and carries the longest clinical track record. It is administered as a daily injection. Semaglutide, sold as Ozempic for diabetes and Wegovy for obesity, followed and quickly established itself as the more potent option in its class; it is given once weekly. Tirzepatide, available as Mounjaro for diabetes and Zepbound for obesity, is the most recent addition and represents a step forward in mechanism — it is the first of its kind to act on two hormonal pathways simultaneously, which accounts for its notably stronger efficacy data.
How Do They Work?
Liraglutide and semaglutide are GLP-1 receptor agonists: they mimic glucagon-like peptide-1 (GLP-1), a hormone released naturally from the intestine after a meal. GLP-1 stimulates insulin secretion in response to rising blood glucose, suppresses the opposing hormone glucagon, slows the rate at which the stomach empties, and reduces appetite by acting on satiety centres in the brain. The result is improved blood glucose control and, at the doses used for weight management, a meaningful reduction in caloric intake.
Tirzepatide adds a second mechanism: it also mimics glucose-dependent insulinotropic polypeptide (GIP), a closely related incretin hormone. The combined activation of both the GLP-1 and GIP receptors appears to produce effects on appetite, insulin sensitivity, and energy metabolism that are greater than either pathway alone. It is this dual action that explains why tirzepatide’s efficacy data consistently surpasses that of its predecessors.
Get in touch with Blooming Clinic to inquire about our services. (Bangkok Branch)
Who Are These Medications Appropriate For?
These treatments are not suitable for everyone and are prescribed only where the clinical benefits are judged to outweigh the risks. For diabetes, they are appropriate for adults with type 2 diabetes who require improved blood glucose control, particularly those who carry excess weight or have elevated cardiovascular risk. For weight management, approved indications extend to adults with a BMI of 30 or above, or those with a BMI of 27 or above alongside weight-related health conditions such as hypertension, dyslipidaemia, or obstructive sleep apnoea.
The patients most likely to benefit are those who have made genuine efforts with dietary and lifestyle changes but have not achieved sufficient results, and who are motivated to commit to medication as one component of a long-term health strategy rather than a standalone solution. Weight loss medications do not work independently of lifestyle; they are consistently most effective when integrated with a programme of supported behaviour change.
Contraindications
These medications are not appropriate for everyone. They should not be used by individuals with type 1 diabetes, during pregnancy or whilst breastfeeding, or by those with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) — a hereditary condition associated with tumours of the endocrine glands. Active pancreatitis or a history of recurrent pancreatitis is also a contraindication. A thorough medical history and clinical assessment are essential before any of these medications are prescribed.
How Effective Are They?
Clinical trial data show a clear hierarchy of efficacy across the three agents, though all three produce clinically meaningful results. Liraglutide, at the doses used for weight management, produces average weight loss of approximately 5 to 8 per cent of body weight over 12 months. The medication also carries a well-established cardiovascular benefit in those with type 2 diabetes, having demonstrated a reduction in major cardiovascular events in the landmark LEADER trial.
Semaglutide produces substantially greater weight reduction, with average losses of 10 to 15 per cent of body weight in clinical trials, and some participants achieving considerably more. Its greater potency is attributed in part to its longer half-life, which allows once-weekly administration and sustains more consistent receptor engagement. Tirzepatide represents the furthest advance in efficacy to date, with average weight losses of 15 to 20 per cent of body weight in clinical studies — approaching results historically associated with bariatric surgery. It is particularly effective in individuals with concurrent type 2 diabetes, in whom both glucose control and weight reduction are clinical priorities.
Individual responses vary considerably. Age, baseline weight, metabolic profile, genetic factors, and adherence to lifestyle measures all influence outcomes. The figures above represent population averages from controlled trial conditions rather than guaranteed individual results.
Quick Comparison
| Feature | Liraglutide | Semaglutide | Tirzepatide |
| Brand names | Victoza (diabetes)Saxenda (obesity) | Ozempic (diabetes)Wegovy (obesity) | Mounjaro (diabetes)Zepbound (obesity) |
| Mechanism | GLP-1 agonist | GLP-1 agonist | Dual GLP-1 + GIP agonist |
| Frequency | Daily injection | Weekly injection | Weekly injection |
| Average weight loss | 5–8% of body weight | 10–15% of body weight | 15–20% of body weight |
| Diabetes efficacy | Improves glucose control; cardiovascular benefit demonstrated | Strong glucose control; cardiovascular benefit | Strongest glucose and weight effect; cardiovascular data accumulating |
| Safety track record | Longest — approved 2010 | Moderate — approved 2017 | Newest — approved 2022 |
Side Effects and Safety
All three medications share a broadly similar side-effect profile, reflecting their shared mechanism of action on the gastrointestinal system. The most common effects are nausea, vomiting, diarrhoea, constipation, bloating, and indigestion. These tend to be most pronounced when treatment begins or when the dose is increased, and they typically diminish as the body adapts over several weeks. Eating smaller portions, avoiding very rich or fatty foods, and remaining well hydrated are the most practical measures for managing this adjustment period.
Less commonly, more serious complications may arise. Pancreatitis — inflammation of the pancreas — has been reported with all three agents and warrants prompt medical attention if severe or persistent abdominal pain develops. Gallbladder problems, including gallstones and cholecystitis, are associated with rapid weight loss of any cause and have been observed in clinical trials across this drug class. In animal studies, GLP-1 receptor agonists have been associated with thyroid C-cell tumours, though this finding has not been established in humans; the contraindication in those with a personal or family history of medullary thyroid carcinoma is a precautionary measure in light of this signal.
The practical advantage of semaglutide and tirzepatide over liraglutide, beyond their greater efficacy, is their once-weekly administration. Daily injections over an extended period place a greater burden on adherence, and the transition to weekly dosing has been associated with improved compliance in clinical practice.
| A Note on Long-Term Safety The long-term safety profile of this medication class continues to be studied. There have been concerns — not yet established in human evidence — about a possible association with pancreatic cancer and chronic pancreatic changes. Rare cases of pancreatitis have been reported, and some patients develop elevated pancreatic enzyme levels without symptoms. Any episode of severe or persistent abdominal pain, nausea, or vomiting should be reported to a clinician promptly. Enzyme levels may be checked as part of routine monitoring, and the medication may be paused or discontinued if concerns arise. These risks should form part of an open and informed discussion between patient and prescribing clinician before treatment begins. |
What to Expect as a Patient
Beginning one of these medications is a gradual process rather than an immediate transformation, and having realistic expectations from the outset makes the experience considerably easier to navigate.
The First Weeks
Most patients notice a reduction in appetite within the first few days, which is the intended effect of the medication. Alongside this, mild nausea, bloating, and indigestion are common as the body adjusts to slower gastric emptying. Eating smaller portions at a measured pace, choosing lighter foods over rich or fatty meals, and remaining well hydrated are practical measures that most patients find helpful during this initial period. The discomfort is generally transient and does not usually require dose adjustment if it remains manageable.
The First Three Months
Weight reduction typically becomes noticeable during this period, though the pace varies between individuals. In those with type 2 diabetes, blood glucose levels often begin to improve relatively early, sometimes before significant weight loss has occurred. If nausea or diarrhoea remain troublesome when the dose is escalated, it is worth discussing with your clinician whether remaining at a lower dose for longer, or adjusting the timing of the injection, might ease the transition.
Six to Twelve Months
This is typically when the most significant weight reduction becomes apparent, with losses of 10 to 20 per cent of body weight depending on the medication and individual response. Many patients also report improvements in energy levels, sleep quality, and general confidence during this phase. Gastrointestinal side effects usually settle considerably by this stage. Maintaining consistent lifestyle habits — a balanced diet and regular physical activity — continues to amplify the medication’s effect.
Long-Term Considerations
For most individuals, the benefits of these medications are contingent on continued use. Weight regain following discontinuation is common, as the appetite-regulatory effect is lost when the drug is withdrawn — a pattern that mirrors the management of other chronic conditions such as hypertension or dyslipidaemia, where long-term medication is the standard of care. Regular clinical review, including monitoring of weight, blood glucose, and relevant safety markers, is an important feature of ongoing management.
Get in touch with Blooming Clinic to inquire about our services. (Bangkok Branch)
Frequently Asked Questions
Are these medications only for people with diabetes?
No. All three are approved for use in adults with type 2 diabetes, but liraglutide and semaglutide are also licensed at higher doses for weight management in individuals without diabetes, and tirzepatide has received similar approval. The eligibility criteria relate to BMI and the presence of weight-related health conditions rather than to diabetes status specifically.
Do I still need to follow a diet and exercise programme?
Yes, and the combination matters. These medications are most effective when used alongside a structured approach to diet and physical activity. They reduce appetite and improve metabolic parameters, but they do not address the behavioural and environmental factors that contribute to weight gain. Patients who engage actively with lifestyle changes alongside medication consistently achieve better outcomes than those who rely on medication alone.
Will the side effects improve over time?
For the majority of patients, yes. Nausea and digestive discomfort are most pronounced during the initial weeks and when doses are increased, and they typically diminish substantially as the body adapts. Starting at the lowest dose and escalating gradually — which is standard clinical practice — is specifically designed to minimise this adjustment period. A small proportion of patients experience ongoing gastrointestinal symptoms that limit tolerability; this should be discussed with a clinician rather than managed through self-adjustment of the dose.
Will I need to take these injections indefinitely?
For many people, long-term use is the realistic expectation if sustained benefit is the goal. Clinical data are consistent that weight regain occurs in the majority of patients who discontinue, because the hormonal appetite suppression that drives the weight loss is no longer present. This does not mean the medication has failed; it reflects the underlying biology of obesity as a chronic condition. The decision about duration of treatment is an individual one, made in consultation with a clinician.
How do I choose between these three medications?
The choice depends on several factors: the degree of weight loss or glucose control required, dosing convenience, the patient’s medical history and contraindications, and availability. As a general pattern, liraglutide offers the longest safety record; semaglutide offers a meaningful step up in efficacy with weekly dosing; tirzepatide offers the strongest efficacy data currently available. A prescribing clinician, taking your full medical history into account, is best placed to advise on which is most appropriate.
What monitoring is required during treatment?
Regular clinical review is an important part of safe and effective management. This typically includes monitoring of body weight, blood glucose and HbA1c in those with diabetes, blood pressure, and renal function. Pancreatic enzyme levels may be checked if there are any symptoms of concern. The frequency of review varies depending on the medication, dose, and individual clinical picture, and will be outlined by your prescribing clinician at the outset of treatment.
In Summary
Liraglutide, semaglutide, and tirzepatide represent a genuine advance in the medical management of obesity and type 2 diabetes. They work through the body’s own hormonal systems, reduce appetite and improve metabolic control, and — at their most effective — produce weight losses that were previously achievable only through surgical intervention. They are not without side effects or contraindications, and they work best as part of a comprehensive approach that includes lifestyle support and clinical monitoring.
The decision about which medication is appropriate — or whether these treatments are suitable at all — requires a careful and individual assessment. A consultation with a qualified clinician ensures that the choice is made on the basis of your specific health history, goals, and circumstances, and that treatment is monitored appropriately from the outset.
Get in touch with Blooming Clinic to inquire about our services. (Bangkok Branch)
References
Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002.
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205–216.
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–515.
Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.
Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring). 2020;28(6):1050–1061.
American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycaemic treatment: Standards of Medical Care in Diabetes — 2024. Diabetes Care. 2024;47(Suppl 1):S158–S178.
Sattar N, McGuire DK. Pathways to cardiovascular benefit with GLP-1 receptor agonists: beyond glucose lowering. Diabetes Obes Metab. 2021;23(1):3–12.
le Roux CW, Astrup A, Fujioka K, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–1409.